SAN DIEGO -- Libra Therapeutics, Inc. today announced the appointment of Philip Lambert, Ph.D., as the company’s first CSO. With more...

Libra launched with $29M to develop novel drug candidates focused on restoring the cellular balance lost in neurodegenerative diseases.